Mirum Pharmaceuticals Launch New Drug for Treatment of Alagille Syndrome
Mirum Pharmaceuticals has recently introduced a new medication called Maralixibat, designed for the treatment of pruritus (itching) associated with Alagille syndrome (ALGS) in patients aged one year and older.
ALGS is a rare genetic disorder characterized by abnormally narrow and malformed bile ducts, leading to the accumulation of bile in the liver and progressive disease.
The mutation in ALGS affects multiple organ systems, including the heart, liver, kidneys, and central nervous system.
Maralixibat obtained breakthrough therapy designation based on positive results from the ICONIC Phase 2b clinical trial conducted in children with ALGS.
Maralixibat belongs to a class of drugs called ileal bile acid transporter inhibitors and is currently being developed for the treatment of pediatric cholestasis, Alagille syndrome, and progressive familial intrahepatic cholestasis.
The breakthrough therapy designation granted by the FDA expedites the development and review process for investigational medicines targeting serious or life-threatening conditions. It signifies that preliminary clinical evidence has demonstrated significant improvement in at least one clinically important outcome compared to existing therapies.
This designation provides the drug with various benefits, including enhanced interaction and guidance from the FDA through the fast track designation program.
